Evidence map›Paper›PMID 24614539›Full record

ArticlePloS one2014

Functional characterization and evaluation of in vitro protective efficacy of murine monoclonal antibodies BURK24 and BURK37 against Burkholderia pseudomallei.

Bhavani V Peddayelachagiri, Soumya Paul, Shivakiran S Makam, Radhika M Urs, Joseph J Kingston, Urmil Tuteja, Murali H Sripathy, Harsh V Batra

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei.Nanomedicine : nanotechnology, biology, and medicine · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Bhavani V PeddayelachagiriMicrobiology Division, Defence Food Research Laboratory, Mysore, Karnataka, India.
Soumya PaulMicrobiology Division, Defence Food Research Laboratory, Mysore, Karnataka, India.
Shivakiran S MakamMicrobiology Division, Defence Food Research Laboratory, Mysore, Karnataka, India.
Radhika M UrsMicrobiology Division, Defence Food Research Laboratory, Mysore, Karnataka, India.
Joseph J KingstonMicrobiology Division, Defence Food Research Laboratory, Mysore, Karnataka, India.
Urmil TutejaMicrobiology Division, Defence Research and Development Establishment, Gwalior, Madhya Pradesh, India.
Murali H SripathyMicrobiology Division, Defence Food Research Laboratory, Mysore, Karnataka, India.
Harsh V BatraMicrobiology Division, Defence Food Research Laboratory, Mysore, Karnataka, India.
Defence Food Research Laboratory · INDefence Research and Development Establishment · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Burkholderia pseudomallei, the causative agent of melioidosis has been recognized by CDC as a category B select agent. Although substantial efforts have been made for development of vaccine molecules against the pathogen, significant hurdles still remain. With no licensed vaccines available and high relapse rate of the disease, there is a pressing need for development of alternate protection strategies. Antibody-mediated passive protection is promising in this regard and our primary interest was to unravel this frontier of specific mAbs against Burkholderia pseudomallei infections, as functional characterization of antibodies is a pre-requisite to demonstrate them as protective molecules. To achieve this, we designed our study on in vitro-based approach and assessed two mAbs, namely BURK24 and BURK37, reactive with outer membrane proteins and lipopolysaccharide of the pathogen respectively, for their ability to manifest inhibitory effects on the pathogenesis mechanisms of B. pseudomallei including biofilm formation, invasion and induction of apoptosis. The experiments were performed using B. pseudomallei standard strain NCTC 10274 and a clinical isolate, B. pseudomallei 621 recovered from a septicemia patient with diabetic ailment. The growth kinetic studies of the pathogen in presence of various concentrations of each individual mAb revealed their anti-bacterial properties. Minimal inhibitory concentration and minimal bactericidal concentration of both the mAbs were determined by using standards of Clinical and Laboratory Standards Institute (CLSI) and experiments were performed using individual mAbs at their respective bacteriostatic concentration. As an outcome, both mAbs exhibited significant anti-Burkholderia pseudomallei properties. They limited the formation of biofilm by the bacterium and completely crippled its invasion into human alveolar adenocarcinoma epithelial cells. Also, the mAbs were appreciably successful in preventing the bacterium to induce apoptosis in A549 cells. The present study design revealed the protection attributes possessed by BURK24 and BURK37 that has to be further substantiated by additional in vivo studies.

Indexed as

AnimalsAnti-Bacterial AgentsAntibodies, MonoclonalAntibody SpecificityAnti-Infective AgentsApoptosisBiofilmsBurkholderia pseudomalleiCell LineCell ShapeDNA DamageEpitopesFemaleFluorescent Antibody TechniqueHumansImmunizationAnti-Bacterial AgentsAntibodies, MonoclonalAnti-Infective AgentsEpitopesProtective Agents

Identifiers

PMID24614539
PMCPMC3948747
OpenAlexW2077623168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.